Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Property:Reference  + (12:59:57, 28 February 2024)
• Property:Age groups specification  + (15:57:04, 29 February 2024)
• Property:Centralized  + (16:54:55, 29 February 2024)
• Property:Perspective  + (16:55:58, 29 February 2024)
• Property:Type of included studies  + (16:57:34, 29 February 2024)
• Property:Specifications concerning AMSTAR 2 tool  + (11:01:24, 3 April 2024)
• Property:Power analysis performed  + (11:50:40, 4 April 2024)
• Property:Reasons given for samples being too small according to power analysis  + (11:51:34, 4 April 2024)
• Property:Other reasons  + (11:54:51, 4 April 2024)
• Property:Testing for normal distribution  + (11:55:18, 4 April 2024)
• Property:Correct application of statistical tests  + (11:55:44, 4 April 2024)
• Property:Correction for multiple testing  + (11:56:14, 4 April 2024)
• Property:Measurement of compliance  + (11:56:28, 4 April 2024)
• Property:Blinding reliable  + (11:57:13, 4 April 2024)
• Property:Check whether blinding was successful  + (11:57:26, 4 April 2024)
• Property:Consistent reporting in numbers  + (11:57:54, 4 April 2024)
• Property:Sufficient washout period  + (11:58:49, 4 April 2024)
• Property:Tested for carry-over effects  + (11:59:03, 4 April 2024)
• Property:Were sequence effects tested  + (11:59:49, 4 April 2024)
• Property:Comprehensive and coherent reporting  + (12:00:01, 4 April 2024)
• Property:Were side effects systematically recorded  + (12:00:24, 4 April 2024)
• Property:Effect sizes reported  + (12:00:54, 4 April 2024)
• Property:Mono- or multicentric  + (12:01:35, 4 April 2024)
• Property:Side effects taken into account in the interpretation of the results  + (11:31:33, 5 April 2024)
• Property:Overall confidence in the results of the review  + (07:47:42, 10 April 2024)

• Property:Blinding  + (09:42:28, 10 April 2024)

• Property:Side Effects / Interactions  + (11:53:16, 16 April 2024)
• Property:Drop-out reasons  + (12:04:15, 16 April 2024)
• Property:Overall Drop-out  + (12:21:03, 16 April 2024)
• Property:Author's Quality Assessment of Included Studies  + (12:55:24, 16 April 2024)
• Property:Number of studies (arm)  + (06:48:53, 25 April 2024)
• Property:Authors Abstract  + (07:32:19, 25 April 2024)
• Property:Specifications on cancer therapies  + (08:12:24, 25 April 2024)
• Property:Further points on quality assessment  + (08:21:30, 25 April 2024)
• Property:Gender specifications  + (08:26:04, 25 April 2024)
• Property:LoE  + (08:40:53, 25 April 2024)
• Property:N randomized  + (08:53:23, 25 April 2024)
• Property:Other sources of bias  + (08:55:54, 25 April 2024)
• Property:Bias due to deviation from intended intervention (adhering to intervention)  + (09:13:14, 25 April 2024)
• Property:Bias due to deviation from intended intervention (assignment to intervention)  + (09:13:36, 25 April 2024)
• Property:Results during intervention  + (09:32:47, 25 April 2024)
• Property:Results after intervention  + (09:32:56, 25 April 2024)
• Category:Publication  + (13:37:03, 8 May 2024)
• Jeon, Y  + (13:58:16, 8 May 2024)
• Category:Author  + (14:03:05, 8 May 2024)
• Property:One-time application  + (07:54:52, 17 May 2024)
• Property:Duration in days  + (08:07:21, 17 May 2024)
• Property:Specifications on analyses  + (08:14:26, 17 May 2024)
• Arbabi-kalati, F  + (11:20:51, 30 May 2024)
• Deghatipour, M  + (11:21:09, 30 May 2024)
• Palmeira, P  + (13:41:33, 30 May 2024)